Ionis, Novartis expand cardio partnership

 

• Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 cardiovascular outcome study with data expected in 2025

• Ionis' new and advanced technologies will be used to create next generation compound targeting Lp(a)

• Ionis will receive a $60 million upfront payment

https://finance.yahoo.com/news/ionis-enters-collaboration-advance-next-110500210.html